You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201421 - 201430 of 204455 results
  1. Novel, Orally-Available Prodrugs for Alzheimer's Disease


    Project Summary for NovelOrally available Prodrugs for Alzheimer s DiseaseDrColton at Duke University Medical Center was among the first to publish that early stages of Alzheimer s disease were characterized by an immuno suppressive condition in the brainColton et alaAs the disease progressesan immuno toxic condition is acquired with disease progression so that at postmortem analysisboth pro infla ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads

    SBC: NAPROGENIX, INC.            Topic: 999

    Abstract A general mechanism for neurodegeneration, including Parkinson's disease and Alzheimer's dementia, is the breakdown and subsequent aggregation of misfolded neuronal proteins. In the “synucleinopathies” for example neurotoxicity is associated with the cleavage of mis-folded alpha-synuclein (ASYN), probably mainly by asparagine endopeptidase (AEP) [Zhang et al 2017]. This generates neur ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an ophthalmic diagnostic probe for neurodegenerativedisorders

    SBC: Amydis Diagnostics Inc.            Topic: NIA

    Project Summary Deposition of amyloid plaques in the brain represents a universal feature Alzheimer s disease pathology and precedes clinical symptoms by several years Currently diagnosis of amyloid associated dementias in individuals showing symptoms of cognitive decline is extremely difficult requiring multiple modes of testing over months to years Early pre symptomatic diagnosis is even m ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health

    SBC: Angion Biomedica Corp.            Topic: N/A

    Cardiovascular disease is the leading cause of morbidity and mortality in the US, afflicting over 58 million Americans. Angiogenic factors can increase vascularization and improve perfusion in ischemia. Scatter factor/hepatocyte growth factor (SF/HGF) may be superior to other angiogenic factors because of multiple actions on components of the angiogenic cascade and anti-apoptotic properties. Our P ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid Satellite Propulsion System Acceptance Testing for USAF Missions

    SBC: APOLLO FUSION, INC.            Topic: J201CSO1

    Apollo Fusion has developed an integrated electric propulsion module for the commercial satellite market: ACE (Apollo Constellation Engine). The integrated propulsion module supports faster delivery and cheaper/easier integration in the satellite. This SBIR Phase II program will support R&D and defense specified modifications of ACE to allow its use in USG missions. The modifications to increase e ...

    SBIR Phase II 2021 Department of DefenseAir Force
  6. Pulmonary valved conduit xenograft with regeneration potential

    SBC: TGen Tech, LLC            Topic: NHLBI

    Congenital heart disease affects approximately 40,000 newborns each year in the U.S. Valve and conduit replacements are needed for absent pulmonary valve, aortic stenosis (Konno procedure, Ross procedure), double outlet right ventricle (Rastelli operation), extracardiac conduit (Fontan operation), pulmonary valve replacement (Tetralogy of Fallot). Materials in current use include homograft blood v ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. IND enabling studies for a personalized immunotherapy for triple negative breast cancer


    Abstract The worldwide incidence of breast cancer ismillionTriple negative breast cancersTNBCaccount forof total breast cancer casesworldwideAnnuallyovernew cases of TNBC are diagnosed in the US aloneThe treatment options for TNBC patients are limitedTriple negative breast cancerTNBCincludes breast cancers that lack estrogen receptorprogesterone receptorand HERproteinsLack of known targets and pat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Functionally Validated Lentiviral siRNA libraries

    SBC: Cellecta, Incorporated            Topic: NCRR

    DESCRIPTION (provided by applicant): Despite rapid advances in elucidating the molecular basis of human diseases, an ostensibly more difficult post-genomic challenge is the functional annotation of disease-specific signaling pathways and integration of this information into the development of novel drugs. RNA interference (RNAi) now makes it possible to use large-scale functional genomic strategie ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health

    SBC: Aethlon Medical, Inc.            Topic: NCI

    The proposed work aims to develop a pre commercial prototype of an exosome isolation device to be used in clinical diagnostic laboratoriesWe will advance the device to facilitate exosome isolation for downstream liquid biopsy tests requiring analysis of proteinDNAor microRNAwhich rely upon acquisition of intact and pure exosomesThe device strategy will be designed to isolate total exosomes and the ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women


    SUMMARY (changes are underlined) The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common problem that affects more than 50 million Americans. Recurrences are common and may be painful. Infection is life-long. Pritelivir is a promising α-helicase inhibitor that proved superior to existin ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government